HEMORRHAGIC shock has been subject of concern to clinicians and has excited considerable interest among scores of investigators. The proper treatment of the patient in hemorrhagic shock constitutes a continuing discussion which has not been fully resolved. For many years, the accepted method of treating the severely hypotensive patient included a vasoconstrictor agent such as levarterenol or metaproteranol sulfate. These agents were effective in producing a marked elevation of blood pressure, but often did not result in the survival of the patient. In the mid-1950's such investigators as Nickerson1 and Lillehei2 suggested that vasodilating agents may offer a more physiologic approach to the treatment of patients in hemorrhagic shock. It was realized that effective tissue perfusion, rather than a normal blood pressure, was a more important factor in the survival of a shocked patient. This current study was conducted to evaluate myocardial performance when induced hemorrhagic shock is
Cook JR, Sherrod TR, Cooley JC. Myocardial Contractile Force in Hemorrhagic Shock: Treatment With Phenoxybenzamine Hydrochloride, Metaproterenol Sulfate, or These Agents Combined. Arch Surg. 1967;95(3):500–510. doi:10.1001/archsurg.1967.01330150176022
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: